New oral pill aims to fight RSV in adults
NCT ID NCT03699202
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral drug called AK0529 (Ziresovir) in adults aged 18 to 75 with respiratory syncytial virus (RSV) infection. Participants receive either the drug or a placebo, and researchers measure how well symptoms improve and track any side effects. The goal is to see if AK0529 can safely reduce RSV symptoms and viral load.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK0529 (Ziresovir)
- What this could lead to
- If successful, this could provide a new oral treatment option for adults with RSV infection, potentially reducing symptoms and viral load.
- What could go wrong
- This is an early phase 2 trial with a small number of participants, so results may not confirm effectiveness or safety. The drug may cause side effects or fail to outperform placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Zunyi Medical University
Zunyi, 563000, China
-
Beijing Anzhen Hospital
Beijing, Beijing Municipality, 100029, China
-
Beijing Ditan Hospital
Beijing, Beijing Municipality, 100015, China
-
Beijing Pinggu Hospital
Beijing, 101200, China
-
Central Hospital of Minhang District, Shanghai
Shanghai, 201199, China
-
China-Japan Friendship Hospital
Beijing, 100029, China
-
Huizhou Municipal Central Hospital
Huizhou, Guangdong, 516001, China
-
Jiangsu Taizhou People's Hospital
Taizhou, Jiangsu, 225300, China
-
Nanjing First Hospital
Nanjing, Jiangsu, 210006, China
-
Nantong First People's Hospital
Nantong, 226001, China
-
People's Hospital of Deyang City
Deyang, Sichuan, 618000, China
-
Qingdao Municipal Hospital
Qingdao, Shandong, 266011, China
-
Quanzhou First Hospital
Quanzhou, Fujian, 362000, China
-
Sanya Central Hospital
Sanya, Hainan, 572000, China
-
Shanghai East Hospital
Shanghai, 200120, China
-
Shenzhen People's Hospital
Shenzhen, 518001, China
-
Suining Central Hopital
Suining, Sichuan, 629000, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, 233004, China
-
The Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan, 571199, China
-
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
-
Xiangtan Central Hospital
Xiangtan, 411100, China
-
Xinxiang First People's Hospital
Xinxiang, 453000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nasal spray vaccine aims to shield children from RSV
- Inhaled interferon could be new weapon against severe RSV in young children
- New antiviral pill aims to shorten RSV symptoms in vulnerable adults
- New rapid test could spot flu and RSV in minutes at your local clinic
- Experimental 'Storm Stopper' therapy tested for COVID-19, flu, and RSV
- Nasal spray vaccine shows promise against common childhood virus